UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17777) 17777
Book / eBook (10) 10
Book Chapter (6) 6
Newspaper Article (6) 6
Newsletter (5) 5
Publication (4) 4
Dissertation (3) 3
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16580) 16580
science & technology (15345) 15345
life sciences & biomedicine (14672) 14672
oncology (10658) 10658
female (10334) 10334
male (8282) 8282
antineoplastic combined chemotherapy protocols - therapeutic use (8264) 8264
middle aged (7432) 7432
aged (6707) 6707
adult (6220) 6220
cancer (5255) 5255
chemotherapy (4956) 4956
treatment outcome (4425) 4425
antineoplastic combined chemotherapy protocols - adverse effects (3970) 3970
animals (3837) 3837
pharmacology & pharmacy (3745) 3745
medicine & public health (3079) 3079
antineoplastic agents - therapeutic use (3033) 3033
care and treatment (2958) 2958
antineoplastic combined chemotherapy protocols - administration & dosage (2919) 2919
research (2439) 2439
neoplasms - drug therapy (2364) 2364
dose-response relationship, drug (2252) 2252
hematology (2128) 2128
drug administration schedule (2061) 2061
antineoplastic agents - administration & dosage (2048) 2048
cell line, tumor (2010) 2010
antineoplastic agents (1986) 1986
mice (1981) 1981
aged, 80 and over (1958) 1958
drug therapy (1941) 1941
antineoplastic combined chemotherapy protocols - pharmacokinetics (1907) 1907
antimitotic agents (1839) 1839
analysis (1812) 1812
tumors (1810) 1810
breast neoplasms - drug therapy (1778) 1778
pharmacology/toxicology (1765) 1765
antineoplastic agents - pharmacology (1764) 1764
clinical trials (1662) 1662
disease-free survival (1580) 1580
breast cancer (1579) 1579
health aspects (1542) 1542
antineoplastic agents - adverse effects (1520) 1520
metastasis (1509) 1509
cancer research (1500) 1500
prognosis (1472) 1472
lung neoplasms - drug therapy (1467) 1467
cancer therapies (1441) 1441
fluorouracil - administration & dosage (1426) 1426
cisplatin - administration & dosage (1424) 1424
adolescent (1399) 1399
combined modality therapy (1344) 1344
pharmacokinetics (1320) 1320
neoplasm staging (1314) 1314
deoxycytidine - analogs & derivatives (1299) 1299
antineoplastic combined chemotherapy protocols - pharmacology (1290) 1290
survival rate (1271) 1271
paclitaxel - administration & dosage (1204) 1204
antineoplastic agents - pharmacokinetics (1198) 1198
survival analysis (1187) 1187
toxicity (1158) 1158
maximum tolerated dose (1152) 1152
child (1131) 1131
dosage and administration (1106) 1106
apoptosis (1067) 1067
doxorubicin - administration & dosage (1063) 1063
patients (1044) 1044
colorectal neoplasms - drug therapy (1042) 1042
apoptosis - drug effects (1041) 1041
hematology, oncology and palliative medicine (1039) 1039
deoxycytidine - administration & dosage (1031) 1031
clinical trials as topic (1030) 1030
neoplasm metastasis (1026) 1026
drug synergism (1023) 1023
carcinoma, non-small-cell lung - drug therapy (1014) 1014
colorectal cancer (990) 990
retrospective studies (976) 976
breast neoplasms - pathology (974) 974
pharmacology (967) 967
camptothecin - analogs & derivatives (961) 961
infusions, intravenous (949) 949
xenograft model antitumor assays (938) 938
young adult (927) 927
administration, oral (893) 893
medical research (878) 878
cisplatin (872) 872
abridged index medicus (846) 846
drug resistance, neoplasm (845) 845
follow-up studies (839) 839
medicine (836) 836
paclitaxel (832) 832
mice, nude (830) 830
studies (801) 801
carboplatin - administration & dosage (796) 796
cell proliferation - drug effects (796) 796
research article (792) 792
child, preschool (791) 791
oncology, experimental (782) 782
science & technology - other topics (765) 765
cyclophosphamide - administration & dosage (759) 759
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17611) 17611
Japanese (195) 195
French (38) 38
German (34) 34
Chinese (16) 16
Spanish (14) 14
Norwegian (9) 9
Portuguese (8) 8
Hungarian (5) 5
Italian (5) 5
Russian (5) 5
Polish (3) 3
Dutch (2) 2
Danish (1) 1
Hebrew (1) 1
Manx (1) 1
Serbian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science (American Association for the Advancement of Science), ISSN 1095-9203, 04/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Index Medicus | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 09/2013, Volume 31, Issue 27, pp. 3327 - 3334
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
...). Response rate and pharmacokinetic analysis were secondary end points. Results Between June 2015 and May 2016, 26 women were enrolled... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 11/2014, Volume 75, Issue 1, pp. 183 - 189
To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.Eligibility criteria... 
Medicine & Public Health | MEK Inhibitor | Afuresertib | Oncology | Cancer Research | Pharmacology/Toxicology | Combination therapy | AKT Inhibitor | Trametinib | MEK inhibitor | AKT inhibitor | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Thiophenes - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Early Termination of Clinical Trials | Pyridones - administration & dosage | Multiple Myeloma - drug therapy | Neoplasms - blood | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Multiple Myeloma - enzymology | Pyrazoles - pharmacokinetics | Multiple Myeloma - blood | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Pyridones - pharmacokinetics | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasms - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Pyrimidinones - pharmacokinetics | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Pyridones - therapeutic use | Pyrimidinones - administration & dosage | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Pyridones - adverse effects | Cohort Studies | Complications and side effects | Medical research | Care and treatment | Type 1 diabetes | Analysis | Gastrointestinal diseases | Multiple myeloma | Melanoma | Medicine, Experimental | Aspartate | Nausea | Tumors | Index Medicus
Journal Article
Investigational new drugs, ISSN 1573-0646, 01/2010, Volume 29, Issue 3, pp. 489 - 498
Journal Article
British journal of cancer, ISSN 1532-1827, 10/2018, Volume 119, Issue 10, pp. 1208 - 1214
Journal Article
Investigational new drugs, ISSN 1573-0646, 10/2014, Volume 33, Issue 1, pp. 201 - 214
Background This phase I/II study determined the maximal tolerable dose, dose limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of ruthenium compound NAMI... 
NAMI-A | Ruthenium | Phase I | Medicine & Public Health | Gemcitabine | Non-small cell lung cancer | Oncology | Phase II | Pharmacology/Toxicology | Clinical study | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ruthenium - administration & dosage | Deoxycytidine - pharmacokinetics | Ruthenium - adverse effects | Adult | Deoxycytidine - adverse effects | Dimethyl Sulfoxide - administration & dosage | Female | Ruthenium - blood | Dimethyl Sulfoxide - adverse effects | Organometallic Compounds - adverse effects | Deoxycytidine - administration & dosage | Carcinoma, Non-Small-Cell Lung - metabolism | Organometallic Compounds - pharmacokinetics | Treatment Outcome | Ruthenium - pharmacokinetics | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Dimethyl Sulfoxide - analogs & derivatives | Deoxycytidine - analogs & derivatives | Dimethyl Sulfoxide - pharmacokinetics | Organometallic Compounds - administration & dosage | Complications and side effects | Dosage and administration | Research | Lung cancer, Non-small cell | Drug therapy | Studies | Clinical trials | Lung cancer | Pharmaceutical sciences | Clinical outcomes | Index Medicus
Journal Article
Blood, ISSN 1528-0020, 09/2018, Volume 132, Issue 11, pp. 1125 - 1133
Journal Article
Journal Article